These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29206629)

  • 1. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
    Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
    Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils.
    Marks-Konczalik J; Costa M; Robertson J; McKie E; Yang S; Pascoe S
    Respir Med; 2015 Jul; 109(7):860-9. PubMed ID: 26033641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
    Watz H; Barnacle H; Hartley BF; Chan R
    Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
    Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
    PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.
    Lomas DA; Lipson DA; Miller BE; Willits L; Keene O; Barnacle H; Barnes NC; Tal-Singer R;
    J Clin Pharmacol; 2012 Mar; 52(3):416-24. PubMed ID: 22090363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
    Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
    Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
    Yang S; Lukey P; Beerahee M; Hoke F
    Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
    Patel NR; Cunoosamy DM; Fagerås M; Taib Z; Asimus S; Hegelund-Myrbäck T; Lundin S; Pardali K; Kurian N; Ersdal E; Kristensson C; Korsback K; Palmér R; Brown MN; Greenaway S; Siew L; Clarke GW; Rennard SI; Make BJ; Wise RA; Jansson P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1009-1019. PubMed ID: 29628759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
    Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
    Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
    Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
    Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
    Newby LK; Marber MS; Melloni C; Sarov-Blat L; Aberle LH; Aylward PE; Cai G; de Winter RJ; Hamm CW; Heitner JF; Kim R; Lerman A; Patel MR; Tanguay JF; Lepore JJ; Al-Khalidi HR; Sprecher DL; Granger CB;
    Lancet; 2014 Sep; 384(9949):1187-95. PubMed ID: 24930728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
    Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
    N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
    Decramer M; Rossi A; Lawrence D; McBryan D
    Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial.
    Tashkin D; Celli B; Kesten S; Lystig T; Decramer M
    Respir Med; 2010 Oct; 104(10):1495-504. PubMed ID: 20418083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
    Inamdar A; Merlo-Pich E; Gee M; Makumi C; Mistry P; Robertson J; Steinberg E; Zamuner S; Learned S; Alexander R; Ratti E
    J Psychopharmacol; 2014 Jun; 28(6):570-81. PubMed ID: 24699061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.